Wednesday, November 25, 2009, 12:08am SGT - The Singapore stock market opens in 8 hours and 52 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Insmed Incorporated (INSM)

On Nov 24: 0.7949 USD  Up 0.0147 (1.88%)  
 MORE ON INSM 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Insmed, Inc. (NCM:INSM) Delayed quote dataEdit
Last Trade:0.7949 USD
Trade Time:Nov 24
Change:Up 0.0147 (1.88%)
Prev Close:0.7802
Open:0.7803
Bid:0.79 x 300
Ask:0.7949 x 100
1y Target Est:2.00
Day's Range:0.7802 - 0.79
52wk Range:0.40 - 2.57
Volume:91,788
Avg Vol (3m):598,540
Market Cap:103.50M
P/E (ttm):0.89
EPS (ttm):0.895
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add INSM to Portfolio   Download Data

 HEADLINES 
•INSMED INC Financials
EDGAR Online Financials (Fri, Nov 13)
•Insmed Still Looks Very Undervalued
at Seeking Alpha (Mon, Nov 9)
•INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Fri, Nov 6)
•Insmed Incorporated Earnings Call scheduled for 8:30 am ET today
CCBN (Fri, Nov 6)
•Specialty Pharma Stock Picks From David Amsellem Of Piper Jaffray
Wall Street Transcript (Fri, Nov 6)
•Q3 2009 Insmed Incorporated Earnings Release - Before Market Open
CCBN (Fri, Nov 6)
•Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009
PR Newswire (Fri, Nov 6)
•Old School Value Stock Portfolio Performance October 2009
at Seeking Alpha (Tue, Nov 3)
•Insmed To Host Third Quarter 2009 Conference Call
PR Newswire (Thu, Oct 22)
•"Best In Class" Formulation Of Fentanyl Seen As Breakthrough Treatment By Ladenburg Thalmann Analyst
Wall Street Transcript (Tue, Oct 20)
•Portfolio Update: Holdings, Performance
at Seeking Alpha (Sun, Oct 4)
•Sirius Breaks the Buck
at Motley Fool (Sat, Sep 19)
•INSMED INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf
EDGAR Online (Thu, Sep 17)
More Headlines for INSM...
 ANALYST 
EPS Est (next year) (Dec-09) :N/A
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company’s primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatm...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices